The words you are searching are inside this book. To get more targeted content, please make full-text search by clicking here.
Discover the best professional documents and content resources in AnyFlip Document Base.
Search
Published by tpham, 2019-10-04 16:07:15

HCP Brochure - Genomic Prediction

GENOMIC PREDICTION
CLINICAL LABORATORY (GPCL)
is a leader in preimplantation genetic testing, combining state- of-the-art genotyping methods with sophisticated modeling
to provide IVF patients with the most accurate prediction of future health risk known to science. GPCL’s testing services are complemented by expert, compassionate genetic counseling to support patients along their path to parenthood.




LifeViewTM (PGT-P) is the world’s first
and only preimplantation genetic testing for polygenic diseases. The test provides IVF patients with unprecedented peace of mind by predicting risk for disorders including:
Type 1 and Type 2 Diabetes
Breast Cancer • Coronary Artery Disease Hypercholesterolemia
GPCL looks at the genetic material in each embryo to determine if the risk for each of these conditions is higher than the average risk in the general population. Patients have the option to screen for one, some or all
of the conditions on the panel.
Please visit gpclaboratory.com for a complete list of conditions which may be assessed for risk. Currently not applicable to all ancestries. Please inquire for more information.


Type 1 Diabetes Types 2 Diabetes Coronary Artery Disease Heart Attack Hypercholesterolemia Hypertension Testicular Cancer Prostate Cancer Malignant Melanoma Basal Cell Carcinoma Intellectual Disability Idiopathic Short Stature
Risk
0.4% High
32% Normal 9.8% Normal 15.7% Normal 0.1% Normal 53% Normal 1.1.% Normal 8.4% Normal 1.9% Normal 27% Normal - Normal - Normal
Avg Ratio Risk
Risk Percentile
0.1% 4.0x 98% 35% 0.9x 42% 33% 03x 2% 15% 1.0x 52% 0.3% 0.3x 3% 50% 1.1x 58% 0.5% 2.2x 85% 11% 0.8x 36% 2.6% 0.7x 39% 30% 0.9x 42% 2.1% - - 2.1% - -


Preimplantation Genetic Testing
for Aneuploidies (PGT-A) screens for chromosome abnormalities with diagnostic accuracy greater than 98%. PGT-A can detect all forms of triploidy, most forms
of uniparental disomy and segmental aneuploidy (10Mb and higher resolution).


Exceptional value defines everything we do. We include ngerprinting to confirm relatedness and QA contamination check of all embryos. Biopsy and saliva kits are provided by GPCL. PGT-A is included at no additional charge with PGT-M, PGT-SR or LifeViewTM testing.
Our reporting structure is streamlined. PGT-A turnaround time is 10 to 14 days. We offer two-week turnaround time for PGT-M, PGT-SR and LifeViewTM results once all samples are in house, and provide you with access to an online portal to track patient samples, upload documents and view reports.
At every step of the way, our professionals are dedicated to working seamlessly and skillfully with your practice. Our genetic counselors will provide your patients with personalized, expert guidance, from the initial 30- to 60-minute counseling session to help patients understand their PGT options, to post-testing follow-up and discussion of results.


Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) screens
for almost any disease of concern with diagnostic accuracy of 97-99%. We can test multiple monogenic conditions with a single sample for the same competitive price.
We are experienced with non-disclosure PGT.


We have experience working with clients all over the world. Interpretation services are provided along with consent forms in any needed language.


Preimplantation Genetic Testing for Structural Arrangements (PGT-SR) detects extra or missing chromosomal material related to a parental chromosome rearrangement
with diagnostic accuracy greater than 99.9%. We have experience testing for all types of structural rearrangements including reciprocal translocations, Robertsonian translocations and inversions. We can potentially differentiate between balanced and normal karyotypes.


As GPCL’s Chief Scienti c Of cer/Lab Director,
Dr. Nathan Robert Treff has a distinguished history in reproductive genetic testing. He is an associate professor at Rutgers University School of Medicine, where he teaches reproductive genetics.
The recipient of two General Program, two SART, and two SRBT Prize Paper Awards, and the 2013 New Investigator Award from ASRM, Dr. Treff
has published over 100 peer-reviewed papers in Reproductive Genetics. He serves as a member of the ASRM Research Committee, Senior Associate Editor of JARG, and Editor of Fertility and Sterility.
Dr. Treff holds a PhD in Biochemistry from Washington State University. He was the Director of Molecular Biology at Reproductive Medicine Associates of New Jersey for 11 years.
NATHAN TREFF, PHD, HCLD (ABB) COFOUNDER, CSO AND CLINICAL LABORATORY DIRECTOR GENOMIC PREDICTION, INC.


Call us at 844-GPCLABS or [email protected]
Genomic Prediction Clinical Laboratory
675 US Highway One, North Brunswick, NJ 08902


Click to View FlipBook Version